The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Forecasted Market Size Trajectory Of The Injectable Targeted Therapy Market From 2026 To 2030?
The injectable targeted therapy market has experienced swift expansion recently. This market is projected to expand from $64.22 billion in 2025 to $71.03 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.6%. Historically, this growth is linked to factors such as rising cancer incidence rates, strides in monoclonal antibody development, greater acceptance of biologic therapies, the proliferation of oncology treatment centers, and heightened clinical research activities in targeted medications.
The injectable targeted therapy market is anticipated to experience substantial growth in the upcoming years, projected to attain a size of $105.2 billion by 2030, expanding at a compound annual growth rate (CAGR) of 10.3%. This expansion during the forecast period is attributed to factors such as increasing approvals of targeted injectable therapies, rising investments in personalized medicine, the expansion of biologics manufacturing capacity, a growing focus on immunotherapy development, and an increasing demand for precision treatment protocols. Key trends for the same period encompass the increasing development of precision oncology injectables, the rising adoption of antibody-based therapeutics, a growing focus on targeted drug delivery systems, the expansion of combination injectable therapies, and an enhanced emphasis on reduced off-target toxicity.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28250&type=smp
What Primary Drivers Are Shaping The Injectable Targeted Therapy Market?
The escalating need for personalized medicine is anticipated to drive the expansion of the injectable targeted therapy market in the future. Personalized medicine defines a healthcare methodology that customizes prevention, diagnosis, and treatment according to an individual’s genetic, environmental, and lifestyle factors. The growth in personalized medicine is fueled by advancements in genomics, which provide a deeper understanding of individual genetic variations, thereby enabling more precise, targeted treatments that enhance patient outcomes and minimize trial-and-error in therapies. Injectable targeted therapy facilitates personalized medicine by delivering drugs specifically designed to address a patient’s unique molecular or genetic disease profile, leading to improved efficacy and fewer side effects. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, in 2023, the FDA approved 16 new personalized treatments for rare disease patients, an increase from six in 2022. The newly approved personalized treatments for 2023 also encompassed seven cancer drugs and three for other diseases and conditions. Therefore, the rising demand for personalized medicine is powering the growth of the injectable targeted therapy market.
How Is The Injectable Targeted Therapy Market Categorized Across Its Segment Groups?
The injectable targeted therapy market covered in this report is segmented –
1) By Type: Monoclonal Antibodies, Small-Molecules, Immunotoxins, Other Types
2) By Mechanism Of Action: Targeted Inhibition of Signal Transduction Pathways, Targeted Delivery Of Cytotoxic Agents, Immunomodulation
3) By Route Of Administration: Intravenous, Subcutaneous, Intramuscular
4) By Application: Oncology, Cardiometabolism, Immunology, Infectious Diseases, Neuroscience, Ophthalmology, Other Applications
5) By End User: Hospitals, Specialty Clinics, Research Laboratories
Subsegments:
1) By Monoclonal Antibodies: Fully Human Antibodies, Humanized Antibodies, Chimeric Antibodies
2) By Small-Molecules: Tyrosine Kinase Inhibitors, Proteasome Inhibitors, Mtor Inhibitors
3) By Immunotoxins: Recombinant Immunotoxins, Chemical Conjugates, Fusion Proteins
4) By Other Types: Antibody-Drug Conjugates, Bispecific Antibodies, Peptide-Based Therapeutics
What Trends Are Shaping The Future Of The Injectable Targeted Therapy Market?
Leading firms within the injectable targeted therapy market are concentrating on creating novel approaches, including subcutaneous injections, to boost drug delivery effectiveness, improve patient adherence, and more precisely address specific disease pathways. A subcutaneous injection is defined as a technique for delivering medication beneath the skin into the adipose tissue directly below the dermis, facilitating a gradual absorption of the drug into the circulatory system. As an illustration, in August 2025, Eisai Co., Ltd., a pharmaceutical firm based in Japan, collaborated with Biogen Inc., a US biotechnology company, and obtained FDA approval for LEQEMBI IQLIK, designed to treat early Alzheimer’s disease. This formulation is a convenient, once-weekly subcutaneous injection intended for the ongoing management of early Alzheimer’s disease, enabling patients to perform self-administration at home following their initial intravenous treatment. Its mechanism involves slowing cognitive deterioration by targeting and eliminating amyloid beta plaques and protofibrils, which are significant contributors to the advancement of Alzheimer’s. This particular formulation decreases the required treatment duration, minimizes systemic adverse effects relative to IV infusions, and reduces the necessity for visits to infusion centers, thereby providing enhanced autonomy for both patients and their care partners.
Which Firms Are Influencing Competition In The Injectable Targeted Therapy Market?
Major companies operating in the injectable targeted therapy market are Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, Novartis AG, AstraZeneca plc, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Eisai Co. Ltd., Genentech Inc., Beigene Ltd., Agenus Inc., Xilio Therapeutics Inc.
Get The Full Injectable Targeted Therapy Market Report:
https://www.thebusinessresearchcompany.com/report/injectable-targeted-therapy-global-market-report
Which Region Leads The Injectable Targeted Therapy Market In Overall Market Size?
North America was the largest region in the injectable targeted therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the injectable targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Injectable Targeted Therapy Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/injectable-targeted-therapy-global-market-report
Browse Through More Reports Similar to the Global Injectable Targeted Therapy Market 2026, By The Business Research Company
Targeted Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/targeted-therapy-global-market-report
Patient Controlled Injectors Market Report 2026
https://www.thebusinessresearchcompany.com/report/patient-controlled-injectors-global-market-report
Injectable Drug Delivery Devices Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model